Global pharmaceutical company Lupin Limited announced on February 27, 2026, that it has received the Establishment Inspection Report (EIR) from the US FDA for its manufacturing facility located in Goa, India. The facility received a satisfactory Voluntary Action Indicated (VAI) classification following an inspection conducted between November 10 and November 21, 2025. This positive outcome underscores Lupin’s ongoing dedication to global quality standards and regulatory compliance.
Positive Regulatory Outcome for Goa Plant
Lupin Limited, a major player in the global pharmaceutical sector, confirmed the receipt of a favorable inspection report from the United States Food and Drug Administration (US FDA) concerning its Goa facility in India. The inspection took place from November 10 to November 21, 2025, culminating in the issuance of the Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) classification, signifying satisfactory compliance.
Management Commentary
Nilesh Gupta, Managing Director of Lupin, expressed pleasure regarding the outcome. He stated that the VAI classification reflects the company’s sustained concentration on quality excellence and regulatory adherence, thereby reinforcing its commitment to providing safe and effective medicines across global markets.
About Lupin Limited
Lupin is headquartered in Mumbai and distributes products in over 100 markets worldwide. The company specializes in various pharmaceutical areas, including branded and generic formulations, complex generics, biotechnology products, and Active Pharmaceutical Ingredients (APIs). Lupin maintains a strong presence in therapeutic areas such as respiratory, cardiovascular, anti-diabetic, and CNS. The company operates 15 state-of-the-art manufacturing sites and 7 research centers globally, supported by a workforce exceeding 24,000 professionals.
Stock Exchange Information
The announcement was made to the stock exchanges, noting the following identifiers:
- BSE Scrip Code: 500257
- NSE Symbol: LUPIN
Source: BSE
